MRNA Moderna Stock Outlook 2026: Does the mRNA Platform Have a Second Act?
Moderna (MRNA) stock outlook 2026: $7.5B cash runway, mRESVIA RSV launch, intismeran autogene Phase 3 with Merck, $1.94B FY2025 revenue, analyst Hold consensus at $36.82 target. Full pipeline, 3 price scenarios, and honest risk assessment for US investors.
MRNA Moderna mRNA
